GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » EBITDA Margin %

Acrux (ARUXF) EBITDA Margin % : -600.00% (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Acrux EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Acrux's EBITDA for the six months ended in Jun. 2024 was $-2.72 Mil. Acrux's Revenue for the six months ended in Jun. 2024 was $0.45 Mil. Therefore, Acrux's EBITDA margin for the quarter that ended in Jun. 2024 was -600.00%.


Acrux EBITDA Margin % Historical Data

The historical data trend for Acrux's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux EBITDA Margin % Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -907.05 -1,165.95 -715.89 -33.16 -158.43

Acrux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -583.64 -324.40 25.90 -90.07 -600.00

Competitive Comparison of Acrux's EBITDA Margin %

For the Biotechnology subindustry, Acrux's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Acrux's EBITDA Margin % falls into.



Acrux EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Acrux's EBITDA Margin % for the fiscal year that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-5.355/3.38
=-158.43 %

Acrux's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-2.718/0.453
=-600.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux  (OTCPK:ARUXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Acrux EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Acrux's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux Business Description

Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.